DHL Group (0H3Q) Receives a Buy from Goldman Sachs
In a report released yesterday, Patrick Creuset from Goldman Sachs maintained a Buy rating on DHL Group (0H3Q – Research Report), with a price target of €48.00. The company's shares closed yesterday at €39.40.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Creuset is a 4-star analyst with an average return of 2.6% and a 60.20% success rate. Creuset covers the Industrials sector, focusing on stocks such as International Consolidated Airlines, DHL Group, and DSV A/S.
In addition to Goldman Sachs, DHL Group also received a Buy from Kepler Capital 's Marc Zeck in a report issued on June 26. However, yesterday, Barclays maintained a Hold rating on DHL Group (LSE: 0H3Q).
0H3Q market cap is currently €45.84B and has a P/E ratio of 13.56.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of 0H3Q in relation to earlier this year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Jefferies Raises Kraft Heinz (KHC) Price Target, Raises Rating to Neutral
The Kraft Heinz Company (NASDAQ:KHC) is one of 10 consumer defensive stocks to buy now. Goldman Sachs has raised its rating on The Kraft Heinz Company (NASDAQ:KHC) to Neutral from Sell, lifting its price target to $27 from $25. The upgrade reflects what the firm describes as a more balanced risk/reward outlook, even as near-term sales pressures persist. In a note to investors, Goldman analysts acknowledged ongoing concerns, including continued softness in scanner data and declining sales and market share across several of Kraft Heinz's core categories. These challenges, they noted, remain central to the company's struggle to regain momentum in a competitive consumer environment. A closeup of an assembly line worker inspecting a newly produced jar of condiments and sauces. However, the firm pointed to Kraft Heinz's portfolio of iconic brands as a key asset. With the company recently announcing a review of strategic alternatives, Goldman sees the potential for shareholder-accretive actions that could drive future upside. While details of any possible actions remain unclear, the review signals management's willingness to pursue structural changes to unlock value. Despite the cautious stance on fundamentals, Goldman now views the downside risk as more limited. As the company evaluates options and works to stabilize performance, the market may begin to respond more favorably to clearer signs of a turnaround. While we acknowledge the potential of KHC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than KHC and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: and 10 Best Wide Moat Dividend Stocks to Invest in. Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds' investor letters by entering your email address below.
Yahoo
an hour ago
- Yahoo
Goldman Sachs Reaffirms 'Buy' Rating on Iovance (IOVA) for Positive Amtagvi Data
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 10 best healthcare penny stocks to buy according to analysts. Goldman Sachs reiterated its 'Buy' rating on Iovance's stock on June 3. The firm also maintained its $34.00 price target for Iovance shares. A close up of a lab technician in a protective suit, working with cells in a petri dish to develop innovative therapeutics for immune-related diseases. Goldman Sachs based its reaffirmation on new data that Iovance presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO data focused on Amtagvi, a tumor-infiltrating lymphocyte (TIL) therapy. The FDA approved the treatment in February 2024 for adult patients with unresectable or metastatic melanoma. The data supported the therapy's safety profile, which, according to Goldman Sachs, reinforces Amtagvi's potential as a significant treatment option. Goldman Sachs's analysts noted that the five-year follow-up data are unprecedented for any therapy in this heavily pretreated advanced melanoma population. To them, the data highlights the durability of Amtagvi's responses. The firm emphasized Amtagvi's successful US launch, with consistent patient demand, enhanced operations at Authorized Treatment Centers (ATCs), and improved out-of-spec rates (manufacturing quality metrics). It also highlighted the drug's first full calendar year of sales in 2025 as a key driver. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a commercial-stage biopharmaceutical company. It develops and markets cell therapies that harness a patient's own immune cells to treat solid tumors. Its lead product is Amtagvi, approved for advanced melanoma, and it also markets Proleukin. Iovance's pipeline includes candidates for cervical cancer, non-small cell lung cancer, and hematologic malignancies. While we acknowledge the potential of IOVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
2 hours ago
- Business Insider
New Buy Rating for Laopu Gold Co. Ltd. Class H (6181), the Basic Materials Giant
In a report released on June 25, Qian Yao from J.P. Morgan maintained a Buy rating on Laopu Gold Co. Ltd. Class H (6181 – Research Report), with a price target of HK$1,249.00. The company's shares closed last Friday at HK$877.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Yao is a 4-star analyst with an average return of 20.2% and a 58.54% success rate. Yao covers the Consumer Cyclical sector, focusing on stocks such as ANTA Sports Products, Chow Tai Fook Jewellery Group, and Shanghai Chicmax Cosmetics Co., Ltd. Class H. Currently, the analyst consensus on Laopu Gold Co. Ltd. Class H is a Strong Buy with an average price target of HK$1,054.00, implying a 20.18% upside from current levels. In a report released on June 27, Nomura also maintained a Buy rating on the stock with a HK$1,023.00 price target.
